在复杂肺部疾病中，表型庆大霉素耐药可能并不表明对庆大霉素反应不佳。
Phenotypic amikacin resistance may not indicate poor response to amikacin in complex pulmonary disease.
作者信息
Minuk L M, Brode S K, Mehrabi M, Sharma M K, Stobart M, Soualhine H, Marras T K
机构信息
Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Division of Respirology, Department of Medicine, University Health Network, Mount Sinai Hospital, Toronto, Ontario, Canada.
出版信息
Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0008424. doi: 10.1128/aac.00084-24. Epub 2024 May 17.
Abstract
When using amikacin to treat complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes or gene mutations.
摘要
在使用阿米卡星治疗复杂性肺部疾病（MAC-PD）时，建议最低抑菌浓度耐药断点≥64 mcg/mL。我们在一组MAC-PD患者的回顾性队列中探究了通过表型药敏试验确定的阿米卡星耐药性是否与临床结局或突变耐药性相关。尽管氨基糖苷类药物暴露较少，但阿米卡星耐药在我们的MAC-PD患者中很常见，但与更差的结局或基因突变无关。
相似文献
1
Phenotypic amikacin resistance may not indicate poor response to amikacin in complex pulmonary disease.
Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0008424. doi: 10.1128/aac.00084-24. Epub 2024 May 17.
2
In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
J Clin Microbiol. 2013 Oct;51(10):3389-94. doi: 10.1128/JCM.01612-13. Epub 2013 Aug 14.
3
Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand.
PLoS One. 2023 Nov 22;18(11):e0294677. doi: 10.1371/journal.pone.0294677. eCollection 2023.
4
Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates.
Sci Rep. 2021 Mar 17;11(1):6108. doi: 10.1038/s41598-021-85721-5.
5
Different clinical features of patients with pulmonary disease caused by various Mycobacterium avium-intracellulare complex subspecies and antimicrobial susceptibility.
Int J Infect Dis. 2020 Sep;98:33-40. doi: 10.1016/j.ijid.2020.06.019. Epub 2020 Jun 10.
6
GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00516-19. Print 2019 Aug.
7
Whole-genome phylogenetic analysis of complex from clinical respiratory samples.
Microbiol Spectr. 2025 Feb 4;13(2):e0160024. doi: 10.1128/spectrum.01600-24. Epub 2025 Jan 10.
8
Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
Infect Genet Evol. 2014 Oct;27:332-8. doi: 10.1016/j.meegid.2014.07.032. Epub 2014 Aug 15.
9
Difference in drug susceptibility distribution and clinical characteristics between and lung diseases in Shanghai, China.
J Med Microbiol. 2021 May;70(5). doi: 10.1099/jmm.0.001358.
10
Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
J Infect Chemother. 2019 Dec;25(12):995-1000. doi: 10.1016/j.jiac.2019.05.028. Epub 2019 Jun 22.
引用本文的文献
1
Risk factors, molecular analysis and treatment outcomes of amikacin-resistant complex pulmonary disease.
ERJ Open Res. 2025 Aug 11;11(4). doi: 10.1183/23120541.01084-2024. eCollection 2025 Jul.
本文引用的文献
1
Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand.
PLoS One. 2023 Nov 22;18(11):e0294677. doi: 10.1371/journal.pone.0294677. eCollection 2023.
2
Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex.
Tuberculosis (Edinb). 2023 Dec;143:102427. doi: 10.1016/j.tube.2023.102427. Epub 2023 Oct 28.
3
Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease.
Chest. 2023 Jul;164(1):53-64. doi: 10.1016/j.chest.2023.02.015. Epub 2023 Feb 17.
4
Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: the potential role of efflux pumps.
J Glob Antimicrob Resist. 2022 Dec;31:345-352. doi: 10.1016/j.jgar.2022.10.015. Epub 2022 Nov 5.
5
Underutilization of nontuberculous mycobacterial drug susceptibility testing in Ontario, Canada, 2010-2015.
J Assoc Med Microbiol Infect Dis Can. 2020 Jun 23;5(2):77-86. doi: 10.3138/jammi.2019-0019. eCollection 2020 Jun.
6
Genetic Determinants Associated with the Intrinsic Resistance to Antibiotics.
Microorganisms. 2021 Dec 7;9(12):2527. doi: 10.3390/microorganisms9122527.
7
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
Clin Infect Dis. 2020 Aug 14;71(4):e1-e36. doi: 10.1093/cid/ciaa241.
8
Different clinical features of patients with pulmonary disease caused by various Mycobacterium avium-intracellulare complex subspecies and antimicrobial susceptibility.
Int J Infect Dis. 2020 Sep;98:33-40. doi: 10.1016/j.ijid.2020.06.019. Epub 2020 Jun 10.
9
Rational Choice of Antibiotics and Media for Complex Drug Susceptibility Testing.
Front Microbiol. 2020 Feb 19;11:81. doi: 10.3389/fmicb.2020.00081. eCollection 2020.
10
Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease.
Eur Respir J. 2019 May 23;53(5). doi: 10.1183/13993003.01636-2018. Print 2019 May.
Zotero 插件